Compounds > gemcitabine
Page last updated: 2024-08-24

gemcitabine and plerixafor

gemcitabine has been researched along with plerixafor in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's3 (50.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Bhardwaj, A; Owen, LB; Singh, AP; Singh, S; Srivastava, SK1
Berr, F; Kiesslich, T; Mayr, C; Namberger, K; Neureiter, D; Pichler, M; Wagner, A1
Arora, S; Carter, JE; Gorman, GS; Khan, MA; Khushman, M; Patel, GK; Singh, AP; Singh, S; Srivastava, SK; Zubair, H1
Bian, W; Liu, JH; Liu, SG; Lv, HT; Wang, WB; Xing, L; Zhang, TF1

Reviews

1 review(s) available for gemcitabine and plerixafor

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for gemcitabine and plerixafor

ArticleYear
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
    British journal of cancer, 2010, Nov-23, Volume: 103, Issue:11

    Topics: Antimetabolites, Antineoplastic; Benzylamines; beta Catenin; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Heterocyclic Compounds; Humans; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, CXCR4; Signal Transduction

2010
Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine.
    Molecular medicine reports, 2015, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Bile Ducts; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclams; Deoxycytidine; Drug Synergism; Epithelial Cells; Gallbladder; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Receptors, CXCR4; Signal Transduction

2015
Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
    The Journal of biological chemistry, 2020, 06-19, Volume: 295, Issue:25

    Topics: Anilides; Animals; Antimetabolites, Antineoplastic; Benzylamines; Cell Communication; Cell Survival; Coculture Techniques; Cyclams; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Hedgehog Proteins; Heterocyclic Compounds; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Pyridines; Reactive Oxygen Species; Receptors, CXCR4; RNA Interference; RNA, Small Interfering; Signal Transduction

2020
The effect of gemcitabine combined with AMD3100 applying to cholangiocarcinoma RBE cell lines to CXCR4/CXCL12 axis.
    Scandinavian journal of gastroenterology, 2021, Volume: 56, Issue:8

    Topics: Benzylamines; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Cholangiocarcinoma; Cyclams; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Receptors, CXCR4

2021